Greg Otterson
Ohio State University
30 Papers
118 Citations
Greg Otterson is an academic researcher from Ohio State University. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Lung cancer. The author has an hindex of 8, co-authored 30 publications.
Chat about Author
Papers
Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer
Benjamin F. Chu,M. J. Karpenko,Zhongfa Liu,Josephine Aimiuwu,Miguel A. Villalona-Calero,Kenneth K. Chan,Michael R. Grever,Greg Otterson +7 more
TL;DR: It is observed that decitabine and valproic acid are an effective combination in reactivating hypermethylated genes as demonstrated by re-expressing fetal hemoglobin in patients with advanced stage NSCLC.
93
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Barbara J. Gitlitz,Eric Bernstein,Edgardo S. Santos,Greg Otterson,Ginger L. Milne,Mary Syto,Francis Burrows,Sara Zaknoen +7 more
TL;DR: Although AP/E seemed to improve TTP and overall survival in a subset of patients aged 65 years or younger, the primary endpoint of the trial was not met and the first randomized placebo-controlled study of a COX-2 inhibitor in NSCLC to use a prospective patient-selection strategy.
35
OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
A. Drilon,Jeffrey W. Clark,Jared Weiss,S-H.I. Ou,D.R. Camidge,Ben Solomon,Greg Otterson,Liza C. Villaruz,G. J. Riely,Rebecca S. Heist,Geoffrey I. Shapiro,Danielle Murphy,Sherry C. Wang,Tiziana Usari,Sherry Li,Keith D. Wilner,Paul K. Paik +16 more
TL;DR: This data indicates that the once-weekly treatment with Crizotinib in patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer is a viable treatment option for these patients with atypical EGFRs.
33
Phase I study of 5-aza-2’-deoxycytidine in combination with valproic acid in patients with NSCLC
M. J. Karpenko,Zhongfa Liu,Josephine Aimiuwu,Li-Shun Wang,X. Wu,Miguel A. Villalona-Calero,Donn C. Young,Kenneth K. Chan,Michael R. Grever,Greg Otterson +9 more
TL;DR: A phase I trial of the DNMT inhibitor 5- aza-2’-deoxycytidine (5-aza-CdR) with the HDAC inhibitor valproic acid (VA) in patients with metastatic NSCLC to determine the safety and tolerability of these agents and to assess alterations of methylation after treatment and to analyze pharmacokinetics (PK).
11
Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia
Ralph V. Boccia,Delong Liu,Peter T. Silberstein,N. S. Tchekmedyian,C. Holladay,Dianne Tomita,G. Rossi,Greg Otterson +7 more
TL;DR: This 16-wk, single-arm, open-label study is designed to assess the effectiveness of DA 300 mcg Q3W in achieving and maintaining a target Hb consistent with evidence-based guidelines in patients (pts) with CIA.
10